TRAX — First Tracks Biotherapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2091349 ·
Last close
$43.57
Market Cap
$1.83B
52W High
$54.78
52W Low
$14.72
ADV30
984,432
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -32,844,000 -31,356,000 170,456,000 155,627,000 19,445,000
Jun 2026 0 — -34,937,000 -33,374,000 183,140,000 168,018,000 14,344,000
Mar 2026 0 — -52,811,000 -50,484,000 290,576,000 248,469,000 33,112,000
Sep 2025 0 — -45,057,000 -41,859,000 — — —

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-112,221,000
Investing CF
$138,240,000
Financing CF
$-43,053,000
CapEx
$-93,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.49
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-55,932,000
Inventory
—
Receivables
$2,869,000
ST Investments
$0
EBIT TTM
$-165,649,000
Pretax Income TTM
$-157,073,000
Interest Exp TTM
—
Analysts
12

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2024 0 -181,101,000 -163,705,000 441,891,000 50,295,000 391,596,000 -125,806,000
Dec 2023 0 -118,461,000 -106,150,000 444,109,000 34,260,000 409,849,000 -93,004,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$183,140,000
Forward EPS
$-3.51

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $25.00 · spot: $44.50 · call volume: 104 · put volume: 8
Expected Move to 2027-04-16: ±$18.90 (42.47%) — implied range $25.60 – $63.40 · ATM straddle on $45.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ETON Eton Pharmaceuticals, Inc. $1.84B $63.65 —
AGIO AGIOS PHARMACEUTICALS, INC. $1.79B $29.89 —
HMDCF HUTCHMED (China) Ltd $1.88B $2.16 —
ZYME Zymeworks Inc. $1.78B $25.84 —
ZBIO Zenas BioPharma, Inc. $1.88B $27.75 —

News headlines (Yahoo Finance, 1h cache)

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
2026-11-03 21:15 · Yahoo
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-03 21:15 · Yahoo
First Tracks Biotherapeutics Announces $200 Million Private Placement
2026-10-15 12:00 · Yahoo
7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data
2026-10-13 12:18 · Yahoo
First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data
2026-10-13 11:16 · Yahoo
First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results
2026-10-13 10:12 · Yahoo
First Tracks climbs on ‘impressive’ celiac study data
2026-10-12 21:26 · Yahoo
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
2026-10-12 20:10 · Yahoo
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
2026-10-12 17:02 · Yahoo
First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results
2026-10-12 12:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.